Omnicell, Inc. (OMCL) EPS Estimated At $-0.04; Capital International Raised Juno Therapeutics (JUNO) Position By $425,250

April 21, 2018 - By Marguerite Chambers

Omnicell, Inc. (NASDAQ:OMCL) Logo

Capital International Inc increased Juno Therapeutics Inc (JUNO) stake by 17.18% reported in 2017Q4 SEC filing. Capital International Inc acquired 9,450 shares as Juno Therapeutics Inc (JUNO)’s stock 0.00%. The Capital International Inc holds 64,450 shares with $2.95 million value, up from 55,000 last quarter. Juno Therapeutics Inc now has $10.10B valuation. It closed at $86.96 lastly. It is down 0.00% since April 21, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect Omnicell, Inc. (NASDAQ:OMCL) to report $-0.04 EPS on May, 3.They anticipate $0.25 EPS change or 86.21% from last quarter’s $-0.29 EPS. After having $0.28 EPS previously, Omnicell, Inc.’s analysts see -114.29% EPS growth. The stock decreased 1.37% or $0.6 during the last trading session, reaching $43.3. About 246,655 shares traded. Omnicell, Inc. (NASDAQ:OMCL) has risen 5.20% since April 21, 2017 and is uptrending. It has underperformed by 6.35% the S&P500.

Investors sentiment increased to 1.67 in 2017 Q4. Its up 0.23, from 1.44 in 2017Q3. It increased, as 25 investors sold JUNO shares while 47 reduced holdings. 45 funds opened positions while 75 raised stakes. 68.38 million shares or 3.41% more from 66.13 million shares in 2017Q3 were reported. Panagora Asset Mngmt has invested 0% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Bbr Prtnrs Ltd stated it has 0.57% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Foresite Cap Management Ii Ltd Limited Liability Company has 85,000 shares for 1.36% of their portfolio. Moreover, Glenmede Trust Comm Na has 0% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 156 shares. 1832 Asset Management LP accumulated 70,900 shares. Utah Retirement System reported 12,700 shares. Cap Interest Ca owns 0.6% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 69,400 shares. Moreover, Partner Fund Management Lp has 2.01% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO). 39,700 are owned by Td Asset Mgmt. Citigroup owns 83,438 shares. Pinnacle stated it has 0.01% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Janney Montgomery Scott Ltd Liability reported 0% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). Raymond James & Assocs holds 50,718 shares or 0% of its portfolio. Sg Americas Securities Limited Company reported 15,377 shares. Jennison Assocs Ltd Co reported 1.73 million shares stake.

Among 19 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 2 have Buy rating, 0 Sell and 17 Hold. Therefore 11% are positive. Juno Therapeutics Inc had 57 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating by Standpoint Research given on Tuesday, December 15. The rating was downgraded by Standpoint Research on Wednesday, January 24 to “Hold”. SunTrust downgraded the shares of JUNO in report on Friday, November 25 to “Hold” rating. On Monday, August 7 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) has “Buy” rating given on Monday, August 24 by Standpoint Research. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) earned “Outperform” rating by Northland Capital on Wednesday, July 22. FBR Capital initiated the stock with “Outperform” rating in Tuesday, August 18 report. The firm earned “Outperform” rating on Monday, November 28 by Leerink Swann. The company was downgraded on Thursday, June 8 by BTIG Research. Leerink Swann maintained Juno Therapeutics, Inc. (NASDAQ:JUNO) rating on Thursday, November 2. Leerink Swann has “Outperform” rating and $56 target.

Capital International Inc decreased Alphabet Inc Cl C stake by 1,660 shares to 3,774 valued at $3.95 million in 2017Q4. It also reduced Cme Group Inc Cl A (NASDAQ:CME) stake by 14,310 shares and now owns 46,650 shares. Johnson And Johnson (NYSE:JNJ) was reduced too.

Investors sentiment increased to 1.12 in Q4 2017. Its up 0.10, from 1.02 in 2017Q3. It is positive, as 14 investors sold Omnicell, Inc. shares while 72 reduced holdings. 27 funds opened positions while 69 raised stakes. 37.38 million shares or 0.77% more from 37.10 million shares in 2017Q3 were reported. Minnesota-based Summit Creek Advsrs Llc has invested 2.07% in Omnicell, Inc. (NASDAQ:OMCL). Delta Asset Ltd Liability Tn owns 31 shares for 0% of their portfolio. Aqr Mngmt Ltd holds 11,743 shares or 0% of its portfolio. Pier Capital Ltd Liability Com stated it has 117,875 shares or 0.98% of all its holdings. 32,881 are owned by Us National Bank De. 1492 Cap Mgmt Ltd Com stated it has 16,878 shares or 0.64% of all its holdings. Moreover, Segall Bryant & Hamill Llc has 0.09% invested in Omnicell, Inc. (NASDAQ:OMCL) for 81,778 shares. State Board Of Administration Of Florida Retirement Sys accumulated 24,786 shares. Ls Investment Advisors Limited Liability Company reported 3,380 shares or 0.01% of all its holdings. Stone Ridge Asset Mgmt holds 0.02% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL) for 7,414 shares. Wellington Management Group Incorporated Limited Liability Partnership stated it has 751,229 shares. Kornitzer Mgmt Incorporated Ks holds 0.13% or 155,240 shares in its portfolio. Rmb Cap Ltd Com accumulated 0.09% or 75,154 shares. Martingale Asset L P owns 45,207 shares for 0.03% of their portfolio. King Luther Mngmt Corporation owns 71,355 shares.

Since December 15, 2017, it had 0 insider purchases, and 5 insider sales for $1.03 million activity. PETERSMEYER GARY S had sold 575 shares worth $25,544 on Thursday, March 15. Kuipers Peter J. had sold 1,926 shares worth $99,559 on Friday, December 15. $361,938 worth of stock was sold by LIPPS RANDALL A on Tuesday, March 6. On Monday, April 16 JOHNSTON DAN S sold $507,248 worth of Omnicell, Inc. (NASDAQ:OMCL) or 11,284 shares.

Among 10 analysts covering Omnicell (NASDAQ:OMCL), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Omnicell had 27 analyst reports since July 31, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of OMCL in report on Friday, July 28 with “Buy” rating. On Friday, October 27 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was maintained by Cantor Fitzgerald on Thursday, October 26 with “Buy”. The firm earned “Buy” rating on Tuesday, July 25 by Cantor Fitzgerald. Oppenheimer maintained it with “Buy” rating and $55.0 target in Thursday, October 19 report. On Monday, June 12 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Piper Jaffray maintained Omnicell, Inc. (NASDAQ:OMCL) on Friday, July 28 with “Hold” rating. Cantor Fitzgerald maintained Omnicell, Inc. (NASDAQ:OMCL) rating on Tuesday, December 5. Cantor Fitzgerald has “Buy” rating and $60.0 target. The stock of Omnicell, Inc. (NASDAQ:OMCL) has “Hold” rating given on Friday, February 2 by Craig Hallum. Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) on Tuesday, December 5 with “Buy” rating.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: